During the past decade, Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 1 clinical trials were completed, i.e. on average, 3.6% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 1 clinical trials were completed. i.e. 7.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 31 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 3 trials sponsored, "Fondazione per la Ricerca Ospedale Maggiore" with 2 trials sponsored, "Incyte Corporation" with 1 trials sponsored and "University of Milano Bicocca" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" #1 collaborator was "AOP Orphan Pharmaceuticals AG" with 1 trials as a collaborator, "CML Advocates Network" with 1 trials as a collaborator, "ERIC Group" with 1 trials as a collaborator, "European Leukemia Net" with 1 trials as a collaborator and "Janssen-Cilag S.p.A." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" are "Chronic Myeloid Leukemia" (7 trials), "Acute Lymphoblastic Leukemia" (5 trials), "Chronic Lymphocytic Leukemia" (4 trials), "Leukemia" (4 trials) and "Acute Lymphoid Leukemia" (2 trials). Many other conditions were trialed in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" in a lesser frequency.

Most popular intervention types in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" are "Drug" (27 trials), "Procedure" (4 trials), "Other" (3 trials), "Behavioral" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ponatinib" (3 trials), "mercaptopurine" (3 trials), "methotrexate" (3 trials), "Dexamethasone" (2 trials) and "Imatinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi". 1 are not yet recruiting, 9 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, 0 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".